NCT01273610View on ClinicalTrials.gov

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 20, 2011

Primary Completion Date

February 22, 2018

Study Completion Date

May 19, 2026

Conditions
Breast NeoplasmsHER2/Neu PositiveGeriatric Health Services
Interventions
DRUG

Lapatinib

250 mg tablets

DRUG

Trastuzumab

Intravenous injection

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (8)

14263

Roswell Park Cancer Institute, Buffalo

19107

Thomas Jefferson University, Philadelphia

27599

Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

27704

Duke University Medical Center, Durham

44106

Case Western Reserve University, Cleveland

91010

City of Hope Medical Center, Duarte

91030

South Pasadena Cancer Center, Pasadena

93534

City of Hope Antelope Valley, Lancaster

Sponsors

Collaborators (2)

GlaxoSmithKline
Novartis
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Novartis

INDUSTRY

lead

City of Hope Medical Center

OTHER

NCT01273610 - Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter